Clinic
Tucson Medical Center
Tucson Medical Center was paid $127.25M by Medicaid between Jan 2018 and Dec 2024, across 578 billing codes. Its largest line is 99284, emergency room visit (serious) — 15% of everything it billed.
33Billing provider infoTUCSON MEDICAL CENTER
TUCSON, AZ 85712
TUCSON, AZ 85712
33aNPI1174512792assigned 10/17/2005
33bProvider typeHearing and Speech Clinic/Center
28Total paid$127.25M
24GClaims3,836,178
24DCodes billed578
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Hearing and Speech Clinic/Center providers in Arizona
Rank by total paid#1 of 7
Median peer was paid$453K
This provider vs. median281×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 472,430 | $14.82M | |
| 2019 | 473,849 | $16.19M | |
| 2020 | 435,844 | $14.31M | |
| 2021 | 619,084 | $19.05M | |
| 2022 | 641,937 | $21.76M | |
| 2023 | 620,581 | $21.68M | |
| 2024incomplete | 572,453 | $19.45M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 81,348 | 74,264 | $19.13M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 10% | 44,515 | 40,027 | $13.13M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.4% | 67,926 | 64,018 | $10.73M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 8.1% | 19,504 | 18,284 | $10.27M |
| G0378 | Hospital observation service, per hour | 6.9% | 56,292 | 34,692 | $8.83M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.1% | 70,366 | 66,845 | $6.55M |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 4.0% | 4,222 | 3,952 | $5.08M |
| C1776 | Joint device (implantable) | 2.6% | 817 | 727 | $3.29M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.1% | 18,655 | 17,183 | $2.72M |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 1.7% | 10,992 | 7,497 | $2.19M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.6% | 8,380 | 8,150 | $2.01M |
| 59025 | Fetal non-stress test | 1.5% | 25,003 | 15,665 | $1.96M |
566 more codes
| 44970 | 1.4% | 606 | $1.76M | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 1.4% | 3,343 | $1.72M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.4% | 3,349 | $1.72M |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.3% | 4,274 | $1.67M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.3% | 4,740 | $1.66M |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.3% | 1,543 | $1.62M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.2% | 33,535 | $1.58M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.1% | 12,447 | $1.44M |
| 93458 | 1.0% | 661 | $1.34M | |
| 88307 | <1% | 2,948 | $1.25M | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 31,274 | $1.05M |
| 47562 | <1% | 399 | $977K | |
| 54161 | <1% | 983 | $952K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 12,919 | $898K |
| 72195 | <1% | 1,418 | $873K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 18,362 | $864K |
| 70486 | <1% | 2,206 | $801K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 6,457 | $665K |
| 76801 | <1% | 5,211 | $611K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,676 | $561K |
| 92579 | <1% | 3,799 | $556K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 21,289 | $537K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 75,052 | $528K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 6,653 | $511K |
| 11045 | <1% | 1,390 | $506K | |
| 87070 | <1% | 15,701 | $500K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 6,085 | $438K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 29,490 | $435K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 731 | $407K |
| 95819 | <1% | 2,861 | $383K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 7,098 | $371K |
| 95811 | <1% | 798 | $368K | |
| 76770 | <1% | 4,021 | $319K | |
| 58571 | <1% | 231 | $318K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 2,150 | $292K |
| 73562 | <1% | 5,570 | $285K | |
| 70491 | <1% | 1,244 | $282K | |
| 27447 | <1% | 181 | $278K | |
| 76870 | <1% | 1,824 | $275K | |
| 47563 | <1% | 84 | $271K | |
| 92587 | <1% | 2,610 | $270K | |
| 64721 | <1% | 289 | $262K | |
| 74018 | <1% | 8,046 | $230K | |
| 93970 | <1% | 5,047 | $207K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,521 | $204K |
| 93971 | <1% | 8,309 | $200K | |
| 73080 | <1% | 2,406 | $188K | |
| 49083 | <1% | 561 | $173K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 25,422 | $172K |
| 92611 | <1% | 900 | $171K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,359 | $171K |
| C1781 | Mesh (implantable) | <1% | 446 | $158K |
| 72100 | <1% | 3,435 | $157K | |
| 86850 | <1% | 12,844 | $155K | |
| 80050 | General health panel | <1% | 2,309 | $150K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 57,590 | $146K |
| 73030 | <1% | 4,060 | $146K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 6,283 | $140K |
| 92557 | <1% | 780 | $139K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 22,627 | $135K |
| 93798 | <1% | 2,831 | $130K | |
| 92523 | <1% | 1,124 | $128K | |
| 74181 | <1% | 1,794 | $121K | |
| 88341 | <1% | 1,006 | $120K | |
| 72131 | <1% | 1,318 | $119K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 6,981 | $116K |
| 78264 | <1% | 537 | $110K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,598 | $108K |
| 70487 | <1% | 272 | $107K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,673 | $100K |
| 76942 | <1% | 193 | $95K | |
| 78227 | <1% | 330 | $94K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 462 | $92K |
| 29881 | <1% | 74 | $91K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 5,714 | $83K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 4,260 | $81K |
| 97597 | <1% | 1,916 | $71K | |
| 64494 | <1% | 246 | $71K | |
| 93976 | <1% | 21,899 | $71K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 107,207 | $70K |
| 97161 | <1% | 2,715 | $66K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 355 | $66K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 324 | $65K |
| 20680 | <1% | 52 | $64K | |
| 97162 | <1% | 3,283 | $62K | |
| 74019 | <1% | 1,305 | $61K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 424 | $61K |
| C1732 | Catheter, electrophysiology, diagnostic/ablation, 3d or vector mapping | <1% | 29 | $61K |
| 80053 | Comprehensive metabolic panel | <1% | 64,496 | $60K |
| 90715 | <1% | 3,494 | $60K | |
| 76536 | <1% | 589 | $60K | |
| 58661 | <1% | 410 | $59K | |
| 73502 | <1% | 2,328 | $59K | |
| 11043 | <1% | 327 | $55K | |
| 71045 | Radiologic examination, chest; single view | <1% | 28,628 | $54K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,581 | $54K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 5,904 | $53K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,855 | $53K |
| 64636 | <1% | 73 | $52K | |
| 10060 | <1% | 1,784 | $51K | |
| 95816 | <1% | 370 | $50K | |
| 73130 | <1% | 3,997 | $49K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 642 | $49K |
| 49650 | <1% | 14 | $48K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 15 | $46K |
| 73630 | <1% | 4,659 | $46K | |
| 71101 | <1% | 1,187 | $46K | |
| 0012A | <1% | 2,263 | $46K | |
| 0011A | <1% | 3,369 | $45K | |
| 74246 | <1% | 370 | $45K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 375 | $44K |
| 92526 | <1% | 2,525 | $43K | |
| 97166 | <1% | 1,452 | $42K | |
| 80061 | Lipid panel | <1% | 11,912 | $42K |
| 71250 | <1% | 848 | $41K | |
| 73610 | <1% | 4,307 | $41K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 68,097 | $40K |
| 64493 | <1% | 215 | $39K | |
| 97802 | <1% | 462 | $39K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 3,433 | $38K |
| 52356 | <1% | 13 | $37K | |
| 73140 | <1% | 1,921 | $37K | |
| 54640 | <1% | 18 | $36K | |
| 82803 | <1% | 2,722 | $36K | |
| 73110 | <1% | 3,289 | $36K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 7,071 | $35K |
| 76885 | <1% | 646 | $34K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 206 | $33K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,399 | $33K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 7,616 | $33K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 22,715 | $32K |
| 99153 | Mod sedat endo service >5yrs | <1% | 3,528 | $31K |
| 77066 | Tomosynthesis, mammo | <1% | 235 | $30K |
| 87506 | <1% | 1,183 | $30K | |
| 88342 | <1% | 5,114 | $29K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 172,041 | $29K |
| 64483 | <1% | 59 | $29K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 46,497 | $29K |
| 72072 | <1% | 1,064 | $27K | |
| 64635 | <1% | 58 | $25K | |
| 92552 | <1% | 363 | $25K | |
| 73090 | <1% | 2,113 | $25K | |
| 50590 | <1% | 17 | $24K | |
| 99157 | <1% | 303 | $24K | |
| 70496 | <1% | 1,238 | $24K | |
| 51600 | <1% | 81 | $23K | |
| 82731 | <1% | 361 | $23K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 10,439 | $22K |
| 73700 | <1% | 153 | $22K | |
| 80074 | <1% | 727 | $21K | |
| 80320 | <1% | 7,245 | $21K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 592 | $21K |
| 86920 | <1% | 1,512 | $21K | |
| 99205 | Prolong outpt/office vis | <1% | 499 | $20K |
| 0042T | <1% | 153 | $20K | |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 81 | $20K |
| 76937 | <1% | 261 | $20K | |
| C1769 | Guide wire | <1% | 5,314 | $19K |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 543 | $18K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 21,089 | $18K |
| 74221 | <1% | 269 | $18K | |
| 76642 | <1% | 1,136 | $18K | |
| 73552 | <1% | 470 | $18K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 27,369 | $18K |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 2,423 | $18K |
| 36561 | <1% | 12 | $17K | |
| C1729 | Catheter, drainage | <1% | 623 | $16K |
| 64495 | <1% | 71 | $16K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 2,832 | $15K |
| 92585 | <1% | 74 | $14K | |
| 74174 | <1% | 144 | $14K | |
| 84702 | <1% | 13,418 | $13K | |
| 26055 | <1% | 13 | $13K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,562 | $13K |
| 73590 | <1% | 2,274 | $13K | |
| 87481 | <1% | 73 | $13K | |
| 75984 | <1% | 12 | $13K | |
| 92550 | <1% | 397 | $12K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 4,574 | $12K |
| 95806 | <1% | 127 | $12K | |
| 96367 | <1% | 956 | $11K | |
| 36430 | <1% | 342 | $11K | |
| 81025 | <1% | 24,773 | $11K | |
| 92582 | <1% | 302 | $11K | |
| 0001A | <1% | 769 | $11K | |
| 80055 | <1% | 105 | $10K | |
| 83516 | <1% | 1,536 | $10K | |
| 0002A | <1% | 548 | $10K | |
| 87186 | <1% | 11,435 | $10K | |
| 72128 | <1% | 102 | $10K | |
| 92610 | <1% | 440 | $10K | |
| 72040 | <1% | 2,282 | $10K | |
| A9270 | Non-covered item or service | <1% | 208,777 | $9K |
| 86803 | <1% | 1,470 | $8K | |
| 82607 | <1% | 1,979 | $8K | |
| 77065 | Tomosynthesis, mammo | <1% | 151 | $8K |
| 93312 | <1% | 81 | $8K | |
| 99223 | Prolong inpt eval add15 m | <1% | 63 | $8K |
| 87081 | <1% | 9,716 | $8K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 5,113 | $7K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 459 | $7K |
| 73060 | <1% | 265 | $7K | |
| 82728 | <1% | 1,628 | $7K | |
| 93017 | <1% | 1,835 | $7K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 115 | $7K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 12,739 | $7K |
| A4648 | Tissue marker, implantable, any type, each | <1% | 13 | $7K |
| 84403 | <1% | 283 | $6K | |
| 20610 | <1% | 73 | $6K | |
| 97165 | <1% | 296 | $6K | |
| 72158 | <1% | 52 | $6K | |
| 83880 | <1% | 6,439 | $6K | |
| 70498 | <1% | 1,277 | $6K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 291 | $6K |
| 94060 | <1% | 117 | $5K | |
| 29581 | <1% | 239 | $5K | |
| 74230 | <1% | 964 | $5K | |
| 92567 | <1% | 5,884 | $5K | |
| 51728 | <1% | 13 | $5K | |
| 85027 | <1% | 5,528 | $4K | |
| 70481 | <1% | 12 | $4K | |
| 84484 | <1% | 47,481 | $4K | |
| 83970 | <1% | 115 | $4K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 76,465 | $4K |
| 36415 | Collection of venous blood by venipuncture | <1% | 186,190 | $4K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 57 | $4K |
| 76010 | <1% | 145 | $4K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 25 | $4K |
| 82043 | <1% | 1,638 | $4K | |
| 58662 | <1% | 12 | $4K | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 476 | $4K |
| 83690 | <1% | 63,446 | $3K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 45 | $3K |
| 81001 | <1% | 51,299 | $3K | |
| 58670 | <1% | 44 | $3K | |
| 76506 | <1% | 39 | $3K | |
| 93880 | <1% | 135 | $3K | |
| 74430 | <1% | 607 | $3K | |
| 86870 | <1% | 14 | $3K | |
| 78306 | <1% | 27 | $3K | |
| 92652 | <1% | 25 | $3K | |
| 86762 | <1% | 406 | $3K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 509 | $3K |
| 82247 | <1% | 42,671 | $2K | |
| 12001 | <1% | 2,025 | $2K | |
| 76830 | Ultrasound, transvaginal | <1% | 4,340 | $2K |
| 70490 | <1% | 13 | $2K | |
| 73521 | <1% | 53 | $2K | |
| 87088 | <1% | 10,178 | $2K | |
| 73660 | <1% | 171 | $2K | |
| 80305 | <1% | 9,261 | $2K | |
| 87400 | <1% | 11,833 | $2K | |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | <1% | 50 | $2K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 18,784 | $2K |
| 73221 | <1% | 15 | $2K | |
| 84481 | <1% | 128 | $2K | |
| C1788 | Port, indwelling (implantable) | <1% | 13 | $2K |
| 87077 | <1% | 6,590 | $2K | |
| 84703 | <1% | 41,750 | $2K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 3,847 | $2K |
| 12002 | <1% | 742 | $2K | |
| 99152 | <1% | 5,793 | $2K | |
| 59020 | <1% | 47 | $2K | |
| 87631 | <1% | 849 | $2K | |
| 80329 | <1% | 10,693 | $2K | |
| 97163 | <1% | 24 | $2K | |
| 92586 | <1% | 16 | $2K | |
| 86703 | <1% | 1,974 | $2K | |
| 86780 | <1% | 555 | $2K | |
| 84153 | <1% | 53 | $2K | |
| 29125 | <1% | 1,481 | $2K | |
| 72192 | <1% | 12 | $2K | |
| 96376 | <1% | 10,134 | $2K | |
| 84450 | <1% | 44,743 | $1K | |
| 99221 | <1% | 17 | $1K | |
| 72141 | <1% | 26 | $1K | |
| 84075 | <1% | 41,849 | $1K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 67 | $1K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 7,614 | $1K |
| 83002 | <1% | 145 | $1K | |
| 85730 | <1% | 13,914 | $1K | |
| 12011 | <1% | 1,960 | $1K | |
| 80076 | <1% | 3,928 | $1K | |
| 82570 | <1% | 2,715 | $1K | |
| 87040 | <1% | 15,606 | $1K | |
| 77080 | <1% | 18 | $1K | |
| 76000 | <1% | 285 | $1K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 19,446 | $1K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 10,657 | $1K |
| 77072 | <1% | 12 | $999.40 | |
| 87493 | <1% | 924 | $994.68 | |
| 82948 | <1% | 16,759 | $990.21 | |
| 82670 | <1% | 28 | $989.20 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 12,713 | $969.29 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 6,329 | $962.92 |
| 87653 | <1% | 568 | $962.36 | |
| 82784 | <1% | 1,118 | $954.23 | |
| 73070 | <1% | 17 | $950.28 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 45,580 | $904.86 |
| 83550 | <1% | 1,445 | $861.91 | |
| 80047 | <1% | 1,071 | $849.47 | |
| 84305 | <1% | 66 | $788.37 | |
| Q3014 | Telehealth originating site facility fee | <1% | 416 | $743.42 |
| 86635 | <1% | 318 | $736.82 | |
| 70360 | <1% | 12 | $715.44 | |
| 82962 | <1% | 35,295 | $705.68 | |
| 87799 | <1% | 46 | $703.92 | |
| 87205 | <1% | 9,114 | $697.95 | |
| 84112 | <1% | 2,782 | $695.62 | |
| 73000 | <1% | 53 | $666.03 | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 53 | $658.79 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 21,487 | $651.70 |
| 81003 | <1% | 62,084 | $650.16 | |
| 85610 | <1% | 30,281 | $611.44 | |
| 87340 | <1% | 1,275 | $610.33 | |
| 83001 | <1% | 180 | $606.76 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 4,188 | $604.69 |
| 87210 | <1% | 11,875 | $602.25 | |
| 84145 | <1% | 11,811 | $568.51 | |
| 73560 | <1% | 398 | $562.03 | |
| 82950 | <1% | 488 | $560.37 | |
| J1815 | Injection, insulin, per 5 units | <1% | 6,934 | $559.31 |
| 85379 | <1% | 9,205 | $528.52 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 52,245 | $523.50 |
| 86038 | <1% | 686 | $519.89 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 24,127 | $509.99 |
| 88304 | <1% | 3,306 | $507.73 | |
| 76882 | <1% | 26 | $501.86 | |
| 87486 | <1% | 7,238 | $489.75 | |
| 87581 | <1% | 7,240 | $482.12 | |
| 76098 | <1% | 12 | $422.51 | |
| 83605 | <1% | 18,504 | $409.38 | |
| 86140 | <1% | 9,286 | $388.31 | |
| J3490 | Unclassified drugs | <1% | 28,451 | $388.19 |
| 72170 | <1% | 294 | $387.84 | |
| 99156 | <1% | 438 | $386.63 | |
| 83735 | <1% | 26,877 | $363.91 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 11,982 | $362.33 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 2,769 | $344.57 |
| 86900 | <1% | 15,539 | $325.07 | |
| 86592 | <1% | 2,891 | $314.20 | |
| 80348 | <1% | 61 | $296.85 | |
| 29105 | <1% | 100 | $295.91 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 80,108 | $294.47 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 11,777 | $294.42 |
| 94664 | <1% | 15,321 | $287.08 | |
| 84550 | <1% | 3,781 | $277.86 | |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | <1% | 540 | $277.45 |
| 86901 | <1% | 15,538 | $275.93 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 4,147 | $262.78 |
| 82140 | <1% | 694 | $254.68 | |
| 80354 | <1% | 67 | $252.70 | |
| 82951 | <1% | 12 | $246.25 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 1,941 | $243.65 |
| 87045 | <1% | 160 | $241.85 | |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 1,396 | $234.07 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 2,732 | $231.55 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 37,707 | $203.21 |
| 74455 | <1% | 55 | $197.13 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 24,579 | $196.82 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 9,016 | $191.42 |
| 84439 | <1% | 6,617 | $188.29 | |
| 82330 | <1% | 878 | $185.65 | |
| 82010 | <1% | 1,988 | $172.92 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 4,068 | $167.40 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,807 | $166.06 |
| 82248 | <1% | 741 | $145.97 | |
| 94729 | <1% | 15 | $135.82 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 20,559 | $125.60 |
| 84030 | <1% | 13 | $124.13 | |
| 83615 | <1% | 3,047 | $117.60 | |
| J1817 | Insulin for administration through dme (i.e., insulin pump) per 50 units | <1% | 965 | $108.33 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 3,875 | $104.05 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 5,722 | $98.49 |
| 80325 | <1% | 178 | $97.75 | |
| 82533 | <1% | 33 | $95.57 | |
| 84460 | <1% | 5,905 | $94.06 | |
| 85651 | <1% | 7,491 | $92.28 | |
| 82550 | <1% | 3,197 | $89.20 | |
| 80069 | <1% | 68 | $86.05 | |
| 84156 | <1% | 898 | $83.08 | |
| 84681 | <1% | 12 | $81.07 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 5,858 | $80.92 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 3,313 | $77.89 |
| 93922 | <1% | 16 | $72.85 | |
| 82565 | <1% | 3,190 | $67.87 | |
| J3372 | Injection, vancomycin hcl (xellia), not therapeutically equivalent to j3370, 500 mg | <1% | 815 | $65.68 |
| L1830 | Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf | <1% | 307 | $62.55 |
| 86225 | <1% | 13 | $62.18 | |
| 87075 | <1% | 562 | $58.04 | |
| 87184 | <1% | 33 | $52.45 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 3,472 | $51.00 |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 366 | $49.78 |
| 84100 | <1% | 4,063 | $47.78 | |
| 92556 | <1% | 604 | $47.76 | |
| 80164 | <1% | 200 | $46.07 | |
| 86431 | <1% | 69 | $44.41 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 2,210 | $44.22 |
| 84132 | <1% | 2,990 | $44.08 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 6,153 | $42.05 |
| 83525 | <1% | 69 | $41.37 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 1,553 | $36.55 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 34,396 | $33.71 |
| 82075 | <1% | 1,708 | $32.51 | |
| 86308 | <1% | 397 | $31.69 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 1,830 | $29.49 |
| 86706 | <1% | 45 | $29.43 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 897 | $29.14 |
| J2704 | Injection, propofol, 10 mg | <1% | 32,224 | $27.63 |
| 85007 | <1% | 3,292 | $24.60 | |
| G0008 | Administration of influenza virus vaccine | <1% | 441 | $23.66 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 2,172 | $23.33 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 4,460 | $22.69 |
| J7121 | 5% dextrose in lactated ringers infusion, up to 1000 cc | <1% | 450 | $22.23 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 2,245 | $22.16 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 181 | $21.25 |
| 87106 | <1% | 27 | $18.75 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 6,611 | $18.20 |
| 80361 | <1% | 177 | $17.29 | |
| 85014 | <1% | 4,734 | $17.12 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 10,499 | $14.11 |
| 81015 | <1% | 430 | $8.56 | |
| C9399 | Unclassified drugs or biologicals | <1% | 2,480 | $6.92 |
| 85018 | <1% | 2,547 | $6.36 | |
| 81002 | <1% | 4,009 | $5.72 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 1,417 | $5.28 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 3,859 | $5.00 |
| 87181 | <1% | 995 | $4.91 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 843 | $4.81 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 2,757 | $3.80 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 22,847 | $3.04 |
| 82270 | <1% | 49 | $2.92 | |
| J0153 | Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | <1% | 1,884 | $2.55 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 22,939 | $1.23 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 4,720 | $0.00 |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 325 | $0.00 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | 0% | 1,568 | $0.00 |
| 82375 | 0% | 361 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 592 | $0.00 |
| 82947 | 0% | 834 | $0.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 427 | $0.00 |
| 84520 | 0% | 2,906 | $0.00 | |
| 88302 | 0% | 554 | $0.00 | |
| 83540 | 0% | 1,478 | $0.00 | |
| 80373 | 0% | 77 | $0.00 | |
| Q9958 | High osmolar contrast material, up to 149 mg/ml iodine concentration, per ml | 0% | 257 | $0.00 |
| A4565 | Slings | 0% | 1,179 | $0.00 |
| 85347 | 0% | 642 | $0.00 | |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | 0% | 452 | $0.00 |
| 80337 | 0% | 46 | $0.00 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 773 | $0.00 |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 459 | $0.00 |
| 29505 | 0% | 12 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 347 | $0.00 |
| 29515 | 0% | 219 | $0.00 | |
| 84295 | 0% | 778 | $0.00 | |
| 82977 | 0% | 161 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 223 | $0.00 |
| 88112 | 0% | 112 | $0.00 | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 0% | 454 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 213 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 168 | $0.00 |
| L4361 | Walking boot, pneumatic and/or vacuum, with or without joints, with or without interface material, prefabricated, off-the-shelf | 0% | 26 | $0.00 |
| 89050 | 0% | 438 | $0.00 | |
| 80346 | 0% | 79 | $0.00 | |
| 15853 | 0% | 59 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 350 | $0.00 |
| G9163 | Spoken language expression functional limitation, projected goal status at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 146 | $0.00 |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 78 | $0.00 |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | 0% | 14 | $0.00 |
| J0735 | Injection, clonidine hydrochloride, 1 mg | 0% | 129 | $0.00 |
| 51784 | 0% | 13 | $0.00 | |
| 88360 | 0% | 396 | $0.00 | |
| C1758 | Catheter, ureteral | 0% | 145 | $0.00 |
| 88333 | 0% | 63 | $0.00 | |
| S0028 | Injection, famotidine, 20 mg | 0% | 251 | $0.00 |
| 36600 | 0% | 64 | $0.00 | |
| 91300 | 0% | 444 | $0.00 | |
| 82785 | 0% | 12 | $0.00 | |
| 77062 | 0% | 53 | $0.00 | |
| J2800 | Injection, methocarbamol, up to 10 ml | 0% | 48 | $0.00 |
| 80202 | 0% | 83 | $0.00 | |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | 0% | 16 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 471 | $0.00 |
| 87641 | 0% | 40 | $0.00 | |
| 83992 | 0% | 73 | $0.00 | |
| 58558 | 0% | 44 | $0.00 | |
| 87102 | 0% | 89 | $0.00 | |
| 85384 | 0% | 17 | $0.00 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 0% | 28 | $0.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 77 | $0.00 |
| 77002 | 0% | 14 | $0.00 | |
| 74300 | 0% | 26 | $0.00 | |
| G8996 | Swallowing functional limitation, current status at therapy episode outset and at reporting intervals | 0% | 16 | $0.00 |
| G8997 | Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 16 | $0.00 |
| J2720 | Injection, protamine sulfate, per 10 mg | 0% | 18 | $0.00 |
| 82365 | 0% | 13 | $0.00 | |
| 87512 | 0% | 46 | $0.00 | |
| Q0239 | Injection, bamlanivimab-xxxx, 700 mg | 0% | 17 | $0.00 |
| G8990 | Other physical or occupational therapy primary functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 12 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 2,446 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 1,043 | $0.00 |
| 82150 | 0% | 767 | $0.00 | |
| 82746 | 0% | 1,804 | $0.00 | |
| 97010 | 0% | 365 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 3,598 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 1,635 | $0.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 389 | $0.00 |
| 87046 | 0% | 160 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 1,783 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 4,954 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 538 | $0.00 |
| 80349 | 0% | 239 | $0.00 | |
| L4350 | Ankle control orthosis, stirrup style, rigid, includes any type interface (e.g., pneumatic, gel), prefabricated, off-the-shelf | 0% | 140 | $0.00 |
| 72020 | 0% | 436 | $0.00 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 1,312 | $0.00 |
| 80353 | 0% | 85 | $0.00 | |
| J1836 | Injection, metronidazole, 10 mg | 0% | 308 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 887 | $0.00 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 638 | $0.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 26 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 2,847 | $0.00 |
| 87807 | 0% | 147 | $0.00 | |
| 80345 | 0% | 72 | $0.00 | |
| 92583 | 0% | 129 | $0.00 | |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 220 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 682 | $0.00 |
| 82040 | 0% | 16 | $0.00 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 393 | $0.00 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | 0% | 163 | $0.00 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 1,087 | $0.00 |
| 90686 | 0% | 423 | $0.00 | |
| 77001 | 0% | 27 | $0.00 | |
| G8982 | Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 127 | $0.00 |
| 95886 | 0% | 28 | $0.00 | |
| 87206 | 0% | 52 | $0.00 | |
| G9162 | Spoken language expression functional limitation, current status at therapy episode outset and at reporting intervals | 0% | 149 | $0.00 |
| 87116 | 0% | 49 | $0.00 | |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 0% | 33 | $0.00 |
| 84402 | 0% | 13 | $0.00 | |
| G8991 | Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 12 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 36 | $0.00 |
| 88300 | 0% | 104 | $0.00 | |
| 51797 | 0% | 13 | $0.00 | |
| 51798 | 0% | 69 | $0.00 | |
| 87428 | 0% | 93 | $0.00 | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 0% | 28 | $0.00 |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | 0% | 142 | $0.00 |
| 88334 | 0% | 20 | $0.00 | |
| C1759 | Catheter, intracardiac echocardiography | 0% | 12 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 109 | $0.00 |
| 99406 | 0% | 25 | $0.00 | |
| 80358 | 0% | 66 | $0.00 | |
| 87015 | 0% | 49 | $0.00 | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 26 | $0.00 |
| J0456 | Injection, azithromycin, 500 mg | 0% | 124 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 134 | $0.00 |
| G8981 | Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 132 | $0.00 |
| C1730 | Catheter, electrophysiology, diagnostic, other than 3d mapping (19 or fewer electrodes) | 0% | 43 | $0.00 |
| 91301 | 0% | 513 | $0.00 | |
| 64484 | 0% | 47 | $0.00 | |
| G9159 | Spoken language comprehension functional limitation, current status at therapy episode outset and at reporting intervals | 0% | 28 | $0.00 |
| 84134 | 0% | 12 | $0.00 | |
| G9160 | Spoken language comprehension functional limitation, projected goal status at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 28 | $0.00 |
| 70544 | 0% | 17 | $0.00 | |
| 84270 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialREICHLING, STEVE (CFO)
| Provider | Location | Paid |
|---|---|---|
| Tucson Medical Center | Tucson, AZ | $11K |
| Tucson Medical Center | Tucson, AZ | $848.26 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.